The association of metabolic syndrome and COVID-19 deterioration
Elise Ouedraogo1, Lucie Allard2, Hélène Bihan3
1Department of Infectious Disease, AP-HP, Avicenne Hospital, Bobigny, France.
Insights
Metabolic syndrome (MetS) is highly prevalent in hospitalized COVID-19 patients. This condition significantly increases the risk of severe COVID-19 outcomes, highlighting its role as an independent risk factor.
Area of Science:
- Cardiology
- Endocrinology
- Infectious Diseases
Background:
- Metabolic syndrome (MetS) is a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes.
- The prevalence and impact of MetS in patients hospitalized with coronavirus disease 2019 (COVID-19) remain areas of active investigation.
Purpose of the Study:
- To determine the prevalence of MetS among patients admitted for COVID-19.
- To evaluate the prognostic significance of MetS in predicting COVID-19 deterioration.
Main Methods:
- A retrospective cohort study included adult patients admitted to COVID-19 units.
- MetS was diagnosed based on the presence of at least three components: android obesity, high HbA1c, hypertension, hypertriglyceridemia, and low HDL cholesterol.
- COVID-19 deterioration was defined as requiring supplemental oxygen (≥6 L/min) within 28 days of admission.
Main Results:
- The study included 155 patients; 81.3% had MetS.
- COVID-19 deterioration occurred in 36.1% of patients.
- MetS was significantly associated with COVID-19 deterioration (41.2% in MetS vs. 13.7% in non-MetS patients, p < 0.01).
Conclusions:
- A high prevalence of MetS (81.3%) was observed in hospitalized COVID-19 patients.
- MetS was identified as an independent risk factor for COVID-19 deterioration, with MetS patients being 5.3 times more likely to experience severe outcomes.
Background And Aims:
To evaluate the prevalence and prognostic value of metabolic syndrome (MetS) in patients admitted for coronavirus disease 2019 (COVID-19).
Methods And Results:
In this monocentric cohort retrospective study, we consecutively included all adult patients admitted to COVID-19 units between April 9 and May 29, 2020 and between February 1 and March 26, 2021. MetS was defined when at least three of the following components were met: android obesity, high HbA1c, hypertension, hypertriglyceridemia, and low HDL cholesterol. COVID-19 deterioration was defined as the need for nasal oxygen flow ≥6 L/min within 28 days after admission. We included 155 patients (55.5% men, mean age 61.7 years old, mean body mass index 29.8 kg/m2). Fifty-six patients (36.1%) had COVID-19 deterioration. MetS was present in 126 patients (81.3%) and was associated with COVID-19 deterioration (no-MetS vs MetS: 13.7% and 41.2%, respectively, p < 0.01). Logistic regression taking into account MetS, age, gender, ethnicity, period of inclusion, and Charlson Index showed that COVID-19 deterioration was 5.3 times more likely in MetS patients (95% confidence interval 1.3-20.2) than no-MetS patients.
Conclusions:
Over 81.3% of patients hospitalized in COVID-19 units had MetS. This syndrome appears to be an independent risk factor of COVID-19 deterioration.
More Related Videos
Related Concept Videos
01:19Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
01:30Coronary Artery Disease I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:30Acute Coronary Syndrome I: Introduction